Pharma Focus Asia

CiRA, Kyoto University and Astellas Pharma Enter into Joint Research Agreement

Tuesday, April 11, 2023

The Centre for iPS Cell Research and Application, Kyoto University and Astellas Pharma entered into the second phase of a joint research agreement to further promote the utilization of differentiated cells and tissues derived from human induced pluripotent stem cells (iPS cells) and to create innovative medical solutions.

The joint research agreement with Astellas, which includes state-of-the-art core technology for drug discovery, will be of critical importance to generating new possibilities of drug discovery using iPS cell technology. This joint research, will contribute to drug discovery and development of treatments for various diseases as soon as possible.

This collaboration between CiRA, with expertise in iPS cells and cell therapy, and Astellas, with proven expertise in drug development, will bring even greater VALUE to patients.

CiRA and Astellas will further promote the use of iPS cell-derived differentiated cells and tissues to create innovative medical solutions to offer new treatment options for patients, thereby contributing to the treatment of diseases with high unmet medical needs.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024